+7.3%
GSK vs FCUV
-96.0%
+103.3%
-22.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | FCUV | Excess | Alpha |
|---|---|---|---|---|
| 1D | -2.3% | -3.0% | +0.6% | -2.3% |
| 7D | -3.0% | +56.3% | -59.3% | -3.0% |
| 30D | +0.4% | +29.4% | -29.0% | +0.4% |
| 3M | -1.2% | -29.4% | +28.2% | -1.1% |
| 6M | +0.9% | +35.8% | -34.9% | +1.1% |
| YTD | +4.0% | -85.9% | +89.9% | +3.2% |
| 1Y | +7.3% | -95.7% | +103.0% | +7.1% |
| All | +7.3% | -96.0% | +103.3% | +7.1% |
Cumulative growth
Daily Returns
Daily percentage return beside FCUV.
Daily Out/Under-Performance
Portfolio return minus FCUV return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × FCUV return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded FCUV wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling